Singapore IVF Treatment Market - Strategic Insights and Forecasts (2025-2030)

The Singapore IVF treatment market is forecast to reach USD 0.26 billion by 2030, demonstrating significant growth from its 2020 valuation of USD 0.10 billion. This expansion is projected at a Compound Annual Growth Rate (CAGR) of 9.71% from 2020 to 2030, indicating a robust upward trend.

The report identifies several strategic drivers, including technological innovations in oocyte rejuvenation techniques, substantial government investments in biomedical research and clinical trials, and rising societal acceptance of delayed family planning. Additionally, strategic clinic expansions by healthcare providers are boosting specialized fertility services to meet growing demand.

Government initiatives significantly boost demand, such as the 2022 scheme providing funding for pre-implantation genetic testing (PGT) during IVF treatment. The Marriage and Parenthood Schemes offer substantial subsidies, including 75% co-funding for various Assisted Reproduction Technology (ART) cycles—up to 3 fresh and 3 frozen cycles—making IVF and related treatments more financially accessible for Singaporean citizens.

Singapore's total fertility rate is projected to fall to 0.97 live births per female in 2024, primarily due to high living costs and deferred childbearing as couples prioritize careers and changing lifestyles. This decline, coupled with an increasing trend of infertility, particularly among women aged 30-34, underscores the growing reliance on IVF treatments, which the government is actively supporting to counteract the low birth rate.

The report specifically highlights technological innovations in oocyte rejuvenation techniques as a key advancement driving progress in the Singapore IVF market. These techniques are crucial for restoring egg viability, which leads to improved outcomes in assisted reproduction and enhances the overall efficacy and success rates of fertility treatments.

Government co-funding through schemes like the Marriage and Parenthood Schemes broadly covers Assisted Reproduction Technology (ART) services. This includes in-vitro fertilisation (IVF) and its variations such as IVF with or without ICSI, in-vitro maturation, donor cycles, and double stimulation, with support for a maximum of 3 fresh and 3 frozen ART cycles.